A “real-world” analysis of millions of patient self-reported treatment records from a migraine smartphone app compares the efficacy of acute migraine medications.
In the 18-month trial, people in the early stages of Alzheimer’s who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug.
The U.S. Food and Drug Administration decision makes GSK’s shot, called Arexvy, the first of several potential vaccines in the pipeline for RSV to be licensed anywhere.
The RESTORE Network is working with a specialized group of experts on clinical trials, testing new therapies and technologies to improve the quality of life for those with neurological disorders.
It is estimated that 11.7 million Canadians are living with diabetes or prediabetes. We know that many patients may not be aware of their condition or may not exhibit any symptoms.
